JWBC
XLRN

John W. Brooker & Co’s Acceleron Pharma XLRN Stock Holding History

John W. Brooker & Co’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$14K – 206
2021
Q1 		$14K Buy
+100
New +$12.9K 0.01% 117

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

John W. Brooker & Co's XLRN Position: Q2 2021 in Review

John W. Brooker & Co sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 100 shares — an estimated $14K sold.

John W. Brooker & Co first reported a position in XLRN in Q1 2021 and held it in 1 quarter. The position peaked at $14K in Q1 2021. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • John W. Brooker & Co reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • John W. Brooker & Co sold 100 Acceleron Pharma shares in Q2 2021, an estimated $14K.
  • John W. Brooker & Co first reported a position in Acceleron Pharma in Q1 2021 and held it in 1 quarter.
  • John W. Brooker & Co's Acceleron Pharma position peaked at $14K in Q1 2021.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on John W. Brooker & Co's 13F filing for Q2 2021, filed 9 Jul 2021.